## ULTA: Ulta Beauty, Inc. - XLY: Consumer Cyclical

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 2.42 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($569.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Ulta Beauty stock reaches all-time high at $612.42 By Investing.com**
- Source: Investing.com Nigeria | 20251222T201015 | Bullish | Relevance: 100%
- Ulta Beauty Inc. (ULTA) has reached an all-time high stock price of $612.42, demonstrating significant growth with a 42.37% surge over the past year. InvestingPro data highlights a 39.04% total return over the last year and a 26.17% gain in the past six months, contributing to a market capitalization of $27.09 billion. Despite its "GOOD" financial health, the stock's P/E ratio of 23.23 and PEG ratio of 4.95 suggest it may be overvalued compared to its InvestingPro Fair Value.

**2. Should DRMTLGY’s Exclusive Ulta Rollout Reshape Ulta Beauty’s (ULTA) Science‑Led Skincare Positioning?**
- Source: Simply Wall Street | 20251221T210840 | Somewhat-Bullish | Relevance: 100%
- Ulta Beauty's exclusive launch of DRMTLGY's clinical skincare line across its 1,400+ stores reinforces its commitment to science-led skincare, appealing to ingredient-conscious shoppers. While this deepens Ulta's focus on high-value products, it doesn't immediately alter its near-term earnings outlook, which still faces challenges from rising costs and competition and is projected to reach $13.8 billion revenue and $1.3 billion earnings by 2028, with a fair value of $603.43.

**3. How Ulta Beauty Inc. (ULTA) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20251223T143800 | Bullish | Relevance: 100%
- This article analyzes Ulta Beauty Inc. (NASDAQ: ULTA), highlighting strong sentiment across all horizons supporting an overweight bias. It details institutional trading strategies, including a long position, a momentum breakout strategy, and a risk-hedging short setup, all derived from AI models. Key findings include a significant risk-reward short setup and multi-timeframe signal analysis, providing support and resistance levels.

**4. Patton Fund Management Inc. Purchases 8,370 Shares of Ulta Beauty Inc. $ULTA**
- Source: MarketBeat | 20251223T124145 | Bullish | Relevance: 100%
- Patton Fund Management Inc. significantly increased its stake in Ulta Beauty Inc. (NASDAQ:ULTA) during the third quarter, acquiring an additional 8,370 shares, bringing its total holdings to 8,943 shares valued at $4.89 million. This makes Ulta Beauty its 17th largest position, representing about 0.9% of its portfolio. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $576.50, and Ulta Beauty recently exceeded quarterly earnings and revenue expectations.

**5. Ulta Beauty stock reaches all-time high at $612.42 By Investing.com**
- Source: Investing.com Australia | 20251223T021226 | Bullish | Relevance: 100%
- Ulta Beauty Inc. stock has reached an all-time high of $612.42, reflecting a 42.37% surge over the past year and a 26.17% gain in the last six months, totaling a market capitalization of $27.09 billion. Despite appearing overvalued with a P/E ratio of 23.23 and a PEG ratio of 4.95 compared to its InvestingPro Fair Value, the company maintains a "GOOD" financial health score, driven by a robust business strategy and positive analyst sentiment. Recent analyst updates from Oppenheimer, UBS, Morgan Stanley, and Evercore ISI have raised price targets, while Ulta Beauty also announced an Executive Severance Plan.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 13, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Oppenheimer | $675 | $615 | +10% |
| 2025-12-08 | Morgan Stanley | $640 | $600 | +7% |
| 2025-12-08 | TD Cowen | $725 | $600 | +21% |
| 2025-12-05 | DA Davidson | $650 | $625 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Oppenheimer | main | Outperform |
| 2025-12-08 | Morgan Stanley | main | Overweight |
| 2025-12-08 | TD Cowen | up | Buy |
| 2025-12-05 | DA Davidson | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.6%)
- Blackrock Inc.: 9.0% (-2.1%)
- JPMORGAN CHASE & CO: 5.5% (+99.0%)
- State Street Corpora: 4.4% (+2.3%)
- Sanders Capital, LLC: 2.8% (+8.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 13 raises (avg +6%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.42 elevated, pricing in significant growth expectations. Forward P/E 21.4x stretched relative to 11% growth. Quality metrics strong (ROE 48%, ROA 15%). Analyst sentiment positive (13 raises, avg +6%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.1B |
| Beta | 0.87 |
| 52W Range | $309.01 - $616.14 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.42 |
| Forward P/E | 21.4 |
| Current P/E | 23.7 |
| YoY Growth | 10.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.4% to -0.1% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.37), confirming momentum. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.13% (CS: 66) | Neutral |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | 1.37 | Bullish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.113x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $604.09
- **Stop Loss:** $569.51 (5.7% risk)
- **Target:** $638.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $15,706.34
- **Portfolio %:** 15.71%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-03-12 (Est: $7.15)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $4.60 | $5.14 | +11.8% |
| 2025Q3 | $5.04 | $5.78 | +14.6% |
| 2025Q2 | $5.80 | $6.70 | +15.5% |
| 2025Q1 | $7.15 | $8.46 | +18.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*